Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (Bupropion XL 300mg Once Daily), Escitalopram Oxalate (Escitalopram, 10mg-20mg Once Daily) in Subjects With Major Depressive Disorder

NCT02191397 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02191397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02191397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (Bupropion XL 300mg Once Daily), Escitalopram Oxalate (Escitalopram, 10mg-20mg Once Daily) in Subjects With Major Depressive Disorder
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
February 10, 2015
Completion date
October 25, 2016
Enrollment
534 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major